Just been looking at some of the AI plays that haven't quite taken off yet, and Recursion Pharmaceuticals keeps popping up in discussions. You've got Nvidia and the mega-cap AI winners everyone knows about, but then there's this biotech angle that's been pretty quiet despite having solid fundamentals. So the question everyone's asking: can RXRX actually bounce back in 2026?

Let me break down what they're actually doing here. Recursion is basically trying to use AI to speed up drug discovery, which honestly sounds like a no-brainer on paper. Their operating system screens clinical compounds and predicts which ones have the best shot at making it through FDA approval. They've been at this since 2013, so they had a real first-mover advantage. The FDA even started phasing out animal testing in favor of AI-based models, which should theoretically be a tailwind for companies like this.

Here's the thing though - they haven't proven the model works yet. Zero approved products. Nothing in late-stage trials. That's a pretty big gap between the theory and execution. What they do have coming up is data from early-stage clinical trials on various candidates over the next year or so. But here's where it gets tricky: most of these are phase 1 studies, which are really just about safety, not whether the drug actually works. Even if everything goes smoothly, you're probably not looking at a major stock move from early-stage data.

The competitive advantage story is getting weaker too. When Recursion started, using AI for drug discovery was novel. Now every major pharma company is doing it. Roche and Sanofi are actually working with them on development, which is good for funding but also shows how commoditized this approach has become.

Looking at their pipeline, REC-617 is interesting - it's a potential cancer drug with a differentiated mechanism that could hit breast, colorectal, and lung cancers. Having partnerships with giants like Roche and Sanofi definitely helps with capital access. But here's the reality: even with promising candidates, biotech companies face massive clinical and regulatory hurdles. One failed trial and you're looking at serious downside.

So can RXRX bounce back? Technically possible, but the bar is high. They need actual clinical wins, not just data that shows safety. The stock has been under pressure for good reason - execution risk is real, and the AI edge they once had is now standard industry practice. For risk-averse investors, this feels like a wait-and-see situation. The potential catalysts are there for 2026, but they'd need to deliver real results for a meaningful bounce back to happen. Right now, the risk-reward doesn't look compelling enough for most portfolios.